A team of scientists at the University of California, Los Angeles (UCLA) have developed a groundbreaking cell-based ...

A new MD Anderson antibody, 77A, restores treatment response in resistant myeloma, lymphoma and solid tumors, offering a ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger ...

OS for Black patients was 57.8 months in those with a favorable ELN cytogenic RS, 14.2 months for those with intermediate RS ...

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood ...

The first 100 bases of many genes show excess mutations, revealing a major genomic weak spot that shapes disease risk and ...

What are organoids and how are they developed? How can they be used to help people and what are the advantages of using them?

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Romidepsin（FK228，AbMole，M2007）是一种去乙酰化酶HDAC抑制剂，主要作用于HDAC1和HDAC2，可通过表观遗传修饰调控基因表达。研究表明，Romidepsin（罗米地辛，CAS ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD1-negativity, and ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease ...